The company has granted the underwriter of the offering a 45-day option to purchase up to an additional 457,500 units to cover over-allotments, if any.
Net proceeds of this offering will be used to fund certain operating expenses and development costs as the company pursues FDA 510(k) clearance of its ProUroScan prostate imaging system and to retire certain short-term liabilities.